<ul><li>London-based Isomorphic Labs has raised $600M in its first external funding round led by Thrive Capital and with participation from GV and Alphabet.</li><li>Isomorphic Labs, founded by Sir Demis Hassabis, uses AI to transform the drug design process and has developed advanced AI models for comprehensive drug design.</li><li>The company, a spin-off of Google DeepMind, utilizes DeepMind's AI software, including AlphaFold, in its drug discovery process.</li><li>The funding will be used to advance AI research and development, expand the team, and further develop the next-generation AI drug design engine.</li></ul>

Alphabet spinout Isomorphic Labs secures €555.4M to further transform drug discovery with AI

Discover more